글로벌 종양괴사인자(TNF) 억제제 약물 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 종양괴사인자(TNF) 억제제 약물 시장

종양괴사인자(TNF) 억제제 약물 시장은 2021년에서 2028년까지의 예측 기간 동안 0.55%의 시장 성장을 목격할 것으로 예상됩니다. 종양괴사인자(TNF) 억제제 약물 시장에 대한 Data Bridge Market Research 보고서는 예측 기간 내내 만연할 것으로 예상되는 다양한 요인에 대한 분석과 통찰력을 제공하고 시장 성장에 미치는 영향을 제공합니다. 전 세계적으로 의료 분야의 성장은 종양괴사인자(TNF) 억제제 약물 시장의 성장을 가속화하고 있습니다.

TNF 억제제는 일반적으로 염증을 멈추는 데 사용되는 약물 유형을 말합니다. 이러한 억제제는 궤양성, 궤양성 대장염, 류마티스, 플라그 건선 및 크론병과 같은 질병을 치료하는 데 널리 사용되며 일반적으로 인간 또는 동물 조직의 항체로 만들어집니다. 이러한 약물은 면역 체계에서 반응을 일으키고 염증을 멈추기 위해 혈액에 삽입됩니다.

The increase in the number of people suffering from Crohn’s disease across the globe acts as one of the major factors driving the growth of tumor necrosis factor (TNF) inhibitor drugs market.The use of TNF inhibitors for supressing the inflammatory response caused by TNF cytokines and the high adoption of inhibitorsfor the treatment of inflammatory and autoimmune diseases, such as psoriasis, cancer and Crohn’s disease, among others, accelerate the market growth. The surge in number of research and development activities in tumor necrosis factor (TNF) inhibitor drugs, and shift in the treatment of autoimmune diseases owning to the targeted action of biologics and the emergence of biosimilars further influence the market. Additionally, increase in cases of autoimmune disorders among population, proper reimbursement policies and growth in ageing population positively affects thetumor necrosis factor (TNF) inhibitor drugs market. Furthermore, increase in consumer demand for cost-effective medicines with improved safety and efficacyextend profitable opportunity to the market players in the forecast period of 2021 to 2028.

On the other hand, high production cost of TNF drug is expected to obstruct the market growth. The rise in the preference for alternative is projected to challenge the tumor necrosis factor (TNF) inhibitor drugs marketin the forecast period of 2021-2028.

This tumor necrosis factor (TNF) inhibitor drugs marketreport provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on tumor necrosis factor (TNF) inhibitor drugs marketcontact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Scope and Market Size

The tumor necrosis factor (TNF) inhibitor drugs marketis segmented on the basis of drug, product, application and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications. 

• On the basis of drug, the tumor necrosis factor (TNF) inhibitor drugs market is segmented into adalimumab, certolizumab, etanercept, golimumab, infliximab, and pipeline analysis.
• On the basis of product, the tumor necrosis factor (TNF) inhibitor drugs market is segmented into humira, enbrel, remicade, simponi and cimzia.
• On the basis of application, the tumor necrosis factor (TNF) inhibitor drugs market is segmented into rheumatoid arthritis, psoriasis, inflammatory bowel disease, ankylosing spondylitis, crohn’s disease, plaque psoriasis, ulcerative colitis, hidradenitissuppurativa, juvenile arthritis, uveitis, and others.
• On the basis of distribution channel, the tumor necrosis factor (TNF) inhibitor drugs marketis segmented intohospital pharmacy, retail pharmacy and online pharmacy.

Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Country Level Analysis

The tumor necrosis factor (TNF) inhibitor drugs market is analyzed and market size insights and trends are provided by country, drug, product, application and distribution channel as referenced above.      

The countries covered in the tumor necrosis factor (TNF) inhibitor drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the tumor necrosis factor (TNF) inhibitor drugs market because of the presence of key manufacturers, proactive government initiatives, and favourable reimbursement policies within the region. Asia-Pacific is expected to witness significant growth during the forecast period of 2021 to 2028 due to the trend of biosimilars in the emerging markets, such as China, India, and South Korea.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

종양괴사인자(TNF) 억제제 약물 시장은 또한 모든 국가에 대한 자세한 시장 분석을 제공합니다. 자본 장비에 대한 의료 지출 증가, 종양괴사인자(TNF) 억제제 약물 시장을 위한 다양한 종류의 제품 설치 기반, 수명선 곡선을 사용한 기술의 영향, 의료 규제 시나리오의 변화 및 종양괴사인자(TNF) 억제제 약물 시장에 미치는 영향. 이 데이터는 2010-2019년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 종양괴사인자(TNF) 억제제 약물 시장 점유율 분석

종양괴사인자(TNF) 억제제 약물 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 위에 제공된 데이터 포인트는 종양괴사인자(TNF) 억제제 약물 시장과 관련된 회사의 초점에만 관련이 있습니다.

종양괴사인자(TNF) 억제제 약물 시장 보고서에서 다루는 주요 기업은 AbbVie Inc., Ablyn, AryogenFarmad, CASI Pharmaceuticals Inc., CELGENE CORPORATION, Celltrion Inc., GlaxoSmithKline plc, HanAllBiopharma, Janssen Global Services, LLC, Leo Pharma, LG Chem, AstraZeneca, Momenta Pharmaceuticals, Novartis AG, PROBIOMED SA de CV, Samsung Bioepis, Sandoz International GmbH, Sanofi, Shanghai Pharmaceutical Group Co., Ltd., FUJIFILM Toyama Chemical Co., Ltd. 등 국내 및 글로벌 기업입니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA) 및 남미에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-46520